ICH stability testing is the internationally harmonised method for proving how long a medicine keeps its quality, safety and efficacy, and in Australia it sits behind every prescription medicine the Therapeutic Goods Administration (TGA) approves. Stability testing exposes a drug substance or a finished drug product to defined temperature and humidity conditions and tracks how its critical quality attributes change across time.
ICH stability testing measures the assay of the active ingredient, the growth of degradation products, appearance, dissolution, pH and moisture content, and the results have to stay within predefined acceptance criteria for the whole claimed shelf life. Good stability data covers the physical, chemical and, where relevant, microbiological attributes of the product, because a medicine can look unchanged while quietly losing potency or growing impurities.
The results answer three practical questions that appear on every pack:
The "ICH" part refers to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, whose Q1 series brings regulators and industry across the major markets onto a common set of rules. That harmonisation matters commercially, because a single, well-designed stability study can support registration applications in many countries rather than being repeated region by region.
Most people say "ICH stability testing" when they mean the whole Q1 group, but each guideline has a specific job. Q1A(R2) is the backbone, setting out study design, storage conditions and testing frequency for new drug substances and products.
The world is divided into four stability testing zones based on average temperature and humidity.
Zone I is temperate,
Zone II is subtropical and Mediterranean,
Zone III is hot and dry, and
Zone IV is hot and humid, split into Zone IVa and the even more demanding Zone IVb.
Each zone carries its own long-term storage condition, from the mild 21°C / 45% RH of Zone I, through 25°C / 60% RH for Zone II, up to 30°C / 65% RH for Zone IVa and 30°C / 75% RH for Zone IVb.
Australia is a continent of many real climates, from tropical Cairns to cool Hobart, yet for medicine registration it is assigned to Climatic Zone II. That assignment is a regulatory classification rather than a weather report, and it gives Australian sponsors a clear benchmark of 25°C / 60% RH for long-term stability studies.
Products intended for tropical export markets in Climatic Zones III and IV, or cases where a sponsor wants a single global stability data package, may still be tested against the harsher conditions such as 30°C / 65% RH or 30°C / 75% RH, but Zone II is the default an Australian submission is measured against.
For a general-case product stored at room temperature, three study arms run side by side. The table below sets out the standard ICH storage conditions that apply to an Australian Zone II submission.
|
Study arm |
Temperature |
Relative humidity |
Minimum period at submission |
|
Long-term |
25°C ± 2°C |
60% RH ± 5% |
12 months |
|
Intermediate |
30°C ± 2°C |
65% RH ± 5% |
6 months |
|
Accelerated |
40°C ± 2°C |
75% RH ± 5% |
6 months |
The intermediate arm is a safety net rather than a routine requirement. It only needs to be reported if a "significant change" shows up during accelerated testing at 40°C / 75% RH. Products with different storage needs follow their own rules: a refrigerated medicine is held long-term at 5°C ± 3°C with accelerated testing at 25°C ± 2°C / 60% RH, while a frozen product sits at around minus 20°C ± 5°C.
Some tropical-market programs also run long-term studies for at least 12 months at 30°C / 65% RH. Getting these setpoints and tolerances right, and holding them for months or years without drift, is the core challenge of any stability program.
A registration study is normally run on at least three primary batches of the drug product, ideally including material made at or near production scale, so the result reflects what patients will receive rather than a one-off laboratory batch. Long-term testing is sampled often at first and then less frequently as confidence builds, typically every three months in the first year, every six months in the second year, and annually after that. Throughout, every critical quality attribute has to remain inside its acceptance criteria, and any result trending toward a limit is investigated rather than ignored.
Accelerated testing is where a formulation is deliberately stressed to expose weaknesses quickly. A "significant change" at the accelerated condition has a precise meaning: a 5% change in assay from the starting value, any degradation product breaching its acceptance limit, or a failure of attributes such as appearance, pH or dissolution.
If that happens, the intermediate condition is brought in to give a more realistic picture of the shelf life. This tiered logic is why the stability chamber has to perform reliably across three very different environments at once.
A full stability study across every strength, pack size and container type can involve an enormous number of samples, so ICH Q1D allows two reduced designs.
Both approaches reduce sample requirements and chamber load without abandoning statistical rigour, but they have to be justified up front, because a regulator will expect the reduced design to still support the proposed shelf life.
Alongside the formal storage conditions, stress testing (also called forced degradation) pushes a drug substance well past normal limits using heat, humidity, acid, base, oxidation and light. The aim is not to set a shelf life but to identify the likely degradation pathways and to confirm that the analytical methods can actually detect the resulting impurities.
Photostability testing under ICH Q1B is a related, separate exposure that checks whether light degrades the product and informs the packaging and storage statement. Understanding these pathways early makes the main stability studies far easier to interpret, because the team already knows what to watch for.
Once the data is in, ICH Q1E describes how to turn numbers into a shelf life. Where an attribute changes over time, statistical evaluation, usually regression analysis, is used to estimate the degradation rate and the point at which the attribute would reach its acceptance limit.
Under defined conditions this analysis can justify a shelf life somewhat longer than the real-time data available at submission, which is how a product can launch with a 24-month expiry on 12 months of long-term data. It is worth distinguishing two related terms here: finished drug products are assigned a shelf life with an expiry date, while drug substances are usually given a retest period, after which a batch is re-tested before use rather than automatically discarded.
The TGA has adopted ICH Q1A(R2) and its companion guidance, so an Australian dossier speaks the same technical language as submissions to the FDA in the United States and to regulators in Europe and Japan. Stability data forms part of the quality module of a registration application, and the expectations do not stop at approval.
Under Good Manufacturing Practice, sponsors keep at least one batch a year on an ongoing stability program to confirm the product still meets specification throughout its labelled shelf life. In practice this means an Australian testing facility needs stability chambers that can be trusted to run continuously for years, not just for the length of a single study, and that keep an unbroken record while they do.
A stability study is only as credible as the environment that produced it. If a chamber drifts, develops hot or cold spots, or loses humidity control overnight, the stability data is compromised and, with it, the shelf-life claim. That is why regulators care as much about the equipment as about the protocol. A capable stability chamber has to hold its setpoint tightly and, just as importantly, keep temperature and humidity uniform across every shelf, so a sample in the top corner sees the same conditions as one beside the sensor.
It also needs traceable calibration, continuous data logging with a tamper-evident audit trail, alarms that flag an excursion the moment it starts, and enough resilience to ride out a power interruption without ruining months of work. Before any samples go in, the chamber is qualified and mapped through installation, operational and performance qualification (IQ, OQ and PQ) to prove it does all of this.
This is where locally built equipment earns its keep. Thermoline Scientific has designed and manufactured temperature and humidity cabinets in Australia for more than 50 years, and its Humiditherm (TRH) range is built for exactly this kind of long-duration, tightly controlled work. The cabinets are available from 300 to 1,350 litres, use a touch-screen STARX controller with on-site and remote monitoring, and combine heating, cooling and humidity control in one platform.
Because they are made and supported here, calibration, servicing and advice come from the same team that built the chamber, backed by a 24-month warranty and a customer base that includes CSIRO, Australian universities and NSW Health. For a laboratory that lives or dies by the integrity of its stability data, that "right first time" engineering and local support removes a lot of risk.
If you are setting up or scaling an ICH-aligned stability program, the Thermoline team can help you match a temperature & humidity chamber to the exact storage conditions, capacity and monitoring your studies call for.
ICH Stability Testing FAQs
Does a stability chamber need to be qualified before a study, and what does that involve?
Before the first sample goes in, the chamber is put through installation, operational and performance qualification (IQ, OQ and PQ), followed by a temperature and humidity mapping study that places sensors throughout the empty and loaded space. Mapping confirms there are no significant hot or cold spots and identifies the best position for the control probe. This documentation becomes part of the audit trail an assessor may ask to see, so it is worth planning the qualification before the study rather than reconstructing it afterwards.
Can one chamber run several ICH conditions at the same time?
Each ICH condition, such as long-term at 25°C / 60% RH or accelerated at 40°C / 75% RH, is a single fixed environment, so a chamber can only hold one at a time. Facilities running a full program therefore dedicate separate chambers to each condition or, at minimum, reserve a chamber for one condition for the duration of the study. This is why capacity planning and buying the right number of cabinets up front matters as much as the specification of any single unit.
What happens if there is a temperature or humidity excursion partway through a study?
An excursion does not automatically void the study, but it must be captured, investigated and assessed for its impact on the samples. This is why continuous data logging and prompt alarms matter so much: they let you prove exactly how far and how long conditions departed from the setpoint, and whether corrective action returned the chamber to specification quickly. Chambers with backup protection and rapid recovery after a power interruption make these events far easier to justify to a regulator.
How is the required chamber capacity worked out for a new program?
Capacity is driven by the number of batches, strengths and pack configurations on study at once, multiplied by the samples pulled at each time point, plus a margin for retention and repeat testing. Because long-term studies can occupy a chamber for two to five years, samples accumulate before older ones are released, so sizing to today's needs alone usually leads to overcrowding. Many laboratories choose a larger cabinet, or plan for a second unit early, so airflow and uniformity are never compromised by a packed shelf.
Are the ICH storage conditions the same for veterinary or complementary medicines?
The scientific principles carry across, but the exact expectations differ by product type and regulator. Human prescription medicines follow the ICH Q1 series through the TGA, veterinary products sit under the related VICH stability guidance, and lower-risk complementary medicines still need evidence that the product stays within specification for its claimed shelf life and storage conditions. Whatever the category, the underlying need is the same: controlled, documented temperature and humidity for the life of the study.
How far in advance should equipment be commissioned before testing begins?
Allow several weeks between delivery and the first sample. The chamber needs to be installed, connected to power and any monitoring system, run through IQ, OQ and PQ, and then mapped both empty and loaded, with time built in to investigate and re-test if the mapping reveals a weak spot. Commissioning early also lets the team confirm alarm routing and data logging are working before a live study depends on them, which is far less stressful than discovering a gap once samples are already inside.